The patent application — 2003-532675 — is owned by the Max Planck Institute, but is exclusively licensed to miRNA drug developer and Alnylam/Isis joint venture Regulus Therapeutics.
The application, No. 20060058266, is entitled "Chemically modified oligonucleotides," and claims "composition and methods for making and using chemically modified oligonucleotide agents for inhibiting gene expression," according to its abstract.
MDRNA, Roche, Arrowhead Research, Rosetta Genomics, Alnylam Pharmaceuticals, Genesis Research and Development
As the Canadian election season heats up, neither major party has really paid much attention to science, according to Nature News.
BBC News says the uncertainty over Brexit is affecting science funding in the UK.
A new app purports to tell users "how gay" they are by looking at their DNA, but experts tell Futurism that the app is bunk.
In Nature this week: human and great ape cerebral organoids reveal aspects of brain development unique to humans, and more.